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1. INTRODUCTION 
1.1 ANALYTICAL CHEMISTRY 
Analytical chemistry1 is the branch of chemistry involved in separating, identifying 
and determining the relative amounts of the components making up a sample of 
matter. It is mainly involved in the qualitative identification or detection of 
compounds and the quantitative measurement of the substances present in bulk and 
pharmaceutical preparation. 
The newer methods for separating and determining chemical species are known 
collectively as instrumental methods of analysis. Most of the instrumental methods fit 
into one of the three following categories viz., spectroscopy, electrochemistry and 
chromatography. 
Advantages of instrumental methods:  
 Small samples can be used  
 High sensitivity is obtained 
 Measurements obtained are reliable 
 Determination is very fast  
 Even complex samples can be handled easily 
Limitations of instrumental methods: 
 An initial or continuous calibration is required 
 Sensitivity and accuracy depends on the instrument  
 Cost of equipment is high 
 Concentration range is limited 
 Specialized training is needed 
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 Sizable space is required     
 
Principle types of instrumentation2-10 
 Spectrometric techniques 
 Ultraviolet and visible spectrophotometry 
 Fluorescence and phosphorescence spectrophotometry 
 Atomic Spectrometry (emission and absorption) 
 Infrared Spectrophotometry 
 Raman Spectroscopy 
 X-Ray Spectroscopy 
 Radiochemical Techniques including activation analysis 
 Nuclear Magnetic Resonance Spectroscopy 
 Electron Spin Resonance Spectroscopy  
 Electrochemical techniques11-20 
 Potentiometry 
 Voltametry 
 Voltametric Techniques 
 Stripping Techniques 
 Amperometric Techniques 
 Colorimetry 
 Electrogravimetry 
 Conductance Techniques 
 
 Chromatographic techniques 
 Gas Chromatography 
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 High performance Liquid Chromatography 
 High performance Thin Layer Chromatography 
Miscellaneous techniques21-25 
 Thermal Analysis 
 Mass Spectrometry 
 Kinetic Techniques 
 Hyphenated techniques26-30 
 GC-MS (Gas Chromatography – Mass Spectrometry) 
 ICP-MS (Inductivity Coupled Plasma - Mass Spectrometry) 
 GC-IR (Gas Chromatography – Infrared Spectroscopy) 
 MS-MS (Mass Spectrometry – Mass Spectrometry 
1.2 ANALYTICAL METHOD DEVELOPMENT 
Method development is done 
1) for new products 
2) for existing products 
Methods are developed for new products when no official methods are available.  
Alternate methods for existing (non-Pharamcopoeial) products are developed to 
reduce the cost and time for better precision and ruggedness. Trial runs are 
conducted, method is optimized and validated.  When alternate method proposed 
is intended to replace the existing procedure, comparative laboratory data 
including merit/demerits are made available. 
 
Steps of method development31: 
Documentation starts at the very beginning of the development process, a system 
for full documentation of the development studies must be established. All data 
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relating to these studies must be recorded in laboratory notebook or an electronic 
database. 
Analyte standard characterization 
a) All known information about the analyte and its structure is collected i.e., 
physical and chemical properties, toxicity, purity, hygroscopic nature, 
solubility and stability. 
b) The standard analyte (100% purity) is obtained.  Necessary arrangement 
is made for the proper storage (refrigerator, desiccators, and freezer).  
c) When multiple components are to be analyzed in the sample matrix, the 
number of components is noted, data is assembled and the availability of 
standards for each one is determined. 
d) Only those methods (MS, GC, HPLC etc.,) that are compatible with 
sample stability are considered. 
Method requirements 
The goals or requirements of the analytical method that need to be developed 
are considered and the analytical figures of merit are defined.  The required 
detection limits, selectivity, linearity, range, accuracy and precision are 
defined. 
Literature search and prior methodology 
The literature for all types of information related to the analyte is surveyed, 
for synthesis, physical and chemical properties, solubility and relevant 
analytical methods.  Books, periodicals, chemical manufacturers and 
regulatory agency compendia such as USP / NF, Association of Official 
Analytical Chemists (AOAC) and American Society for Testing and Materials 
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(ASTM) publications are reviewed.  Chemical Abstracts Service (CAS) 
automated computerized literature searches are convenient.  
Choosing a method 
a) Using the information in the literatures and prints, methodology is 
adapted.  The methods are modified wherever necessary.  Sometimes it is 
necessary to acquire additional instrumentation to reproduce, modify, 
improve or validate existing methods for in-house analytes and samples. 
b) If there is no prior method for the analyte in the literature, from analogy, 
the compounds that are similar in structure and chemical properties are 
investigated and are worked out. There is usually one compound for 
which analytical method already exist that is similar to the analyte of 
interest. 
 
Instrumental setup and initial studies 
a) The required instrumentation is setup. Installation, operational and 
performance qualification of instrumentation using laboratory standard 
operating procedures (SOP’s) are verified. 
b) Always new consumables (e.g. solvents, filters and gases) are used, for 
example, method development is never started, on a HPLC column that 
has been used earlier.  
c) The analyte standard in a suitable injection / introduction solution and in 
known concentrations and solvents are prepared.  It is important to start 
with an authentic, known standard rather than with a complex sample 
matrix.  If the sample is extremely close to the standard (e.g., bulk drug), 
then it is possible to start work with the actual sample. 
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d) Analysis is done using analytical conditions described in the existing 
literature. 
Optimization32 
During optimization one parameter is changed at a time, and set of conditions 
are isolated, rather than using a trial and error approach.  Work has been done 
from an organized methodical plan and every step is documented (in a lab 
notebook) in case of dead ends. 
Documentation of analytical figures of merit 
The originally determined analytical figures of merit Limit of quantitation 
(LOQ), Limit of detection (LOD), linearity, time per analysis, cost, sample 
preparation etc., are documented. 
Evaluation of method development with actual samples 
The sample solution should lead to unequivocal, absolute identification of the 
analyte peak of interest apart from all other matrix components.  
Determination of percent recovery of actual sample and demonstration 
of quantitative sample analysis 
Percent recovery of spiked, authentic standard analyte into a sample matrix 
that is shown to contain no analyte is determined.  Reproducibility of 
recovery (average ± standard deviation) from sample to sample and whether 
recovery has been optimized has been shown.  It is not necessary to obtain 
100% recovery as long as the results are reproducible and known with a high 
degree of certainty. 
The validity of analytical method can be verified only by laboratory studies.  
Therefore documentation of the successful completion of such studies is a 
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basic requirement for determining whether a method is suitable for its 
intended applications. 
Strategy for Method Development: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Choose detector and detector settings 
Optimize separation conditions 
Choose method, preliminary run, estimate best separation conditions 
Qualitative method 
Validate the method for release to routine laboratory 
Quantitative calibration 
Need for special procedure, sample pre-treatment 
Information on sample, define separation goals 
Recover purified 
material method 
Check for problems on requirement for special procedure 
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1.3 Method Validation 
Validation is defined as follows by different agencies: 
Food and Drug administration (FDA): Establishing documentation evidence, 
which provides a high degree of assurance that specific process, will consistently 
produce a product meeting its predetermined specification and quality attributes.  
World Health Organization33 (WHO): Action of providing that any procedure, 
process, equipment, material, activity, or system actually leads to the expected 
results. 
European Committee (EC): Action of providing in accordance with the 
principles of good manufacturing practice, that any procedure, process, 
equipment material, activity or system actually lead to the expected results.  In 
brief validation is a key process for effective Quality Assurance. 
Analytical method validation 
Analytical monitoring of a pharmaceutical product or of specific ingredients 
within the product is necessary to ensure its safety efficacy throughout all phases 
of its shelf life.  Such monitoring is in accordance with the specifications 
elaborated during product development.   
Analytical method validation is the corner stone of process validation without a 
proven measurement system it is impossible to confirm whether the 
manufacturing process has done what it purports to do. All new analytical 
methods developed are validated. 
Steps followed for validation procedures 
1. Proposed protocols or parameters for validations are established 
2. Experimental studies are conducted 
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3. Analytical results are evaluated 
4. Statistical evaluation is carried out 
5. Report is prepared documenting all the results 
Table I: Validation Parameters Recommended by International Conference 
on Harmonization (ICH) 
ASSAY TYPE VALIDATIONS 
Identification tests are intended to ensure the identity of an 
analyte in a sample.  This is normally achieved by comparison 
of a property of the sample to that of a reference standard. 
Specificity 
Different validation characteristics are required for a 
quantitative test than for a limit test. 
Accuracy 
Precision 
Specificity 
Detection limit 
Quantitation 
limit 
Linearity 
Range 
Impurities limits are intended to reflect the purity 
characteristics of the sample. 
Specificity 
Detection limit 
Content / Potency, Dissolution are intended to measure the 
analyte present in a given sample.  A quantitative measurement 
of the major component (s) in the drug substance. 
Accuracy 
Precision 
Specificity 
Linearity 
Range 
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In the ICH – 2QA34 – Text on validation analytical procedures, validation 
characteristics versus type of analytical procedures are shown in Table II. 
Table II: Validation Characteristics versus Type of Analytical Procedures 
Test of Impurities 
Type of 
Procedure 
Identification Quantitation Limit 
Dissolution 
Measurement  
(Content / 
Potency) 
Accuracy No Yes No Yes 
Precision 
or  Repeatability 
No Yes No Yes 
Intermediate 
Precision 
No Yesa No Yesa 
Specificity Yes Yes Yes Yes 
Detection Limit No Nob Yes No 
Quantitation 
Limit 
No Yes No No 
Linearity No Yes No Yes 
Range No Yes No Yes 
  a, When reproducibility is performed, intermediate precision is not needed  
  b, May be needed in some cases 
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The comparison of different official guidelines in case of parameters required to 
be validated for different assays is shown in Table III.  
Table III: Comparative Table Representing FDA, USP and ICH 
Requirements 
Criteria GMP FDA USP ICH 
Accuracy x x x X 
Reproducibility x   X 
Sensitivity x    
Specificity x x x X 
Linearity  x x X 
Precision  x x X 
Detection Limit   x X 
Quantitation Limit   x X 
Range   x X 
Recovery  x   
Ruggedness  x x  
 
Analytical methods are required for the identification, batch analysis and storage stability 
data for active constituents of Pharmaceutical products, and for post-registration 
compliance purposes. Analytical method development as a first step is carried out to 
ensure that the API used and the dosage forms that are developed and manufactured for 
human consumption are meeting the regulated quality norms. Every newly developed 
method must be validated prior to sample analysis. Validation must also be repeated if a 
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parameter has been modified or if the validation was strongly performed in another 
laboratory, to ensure that the methods are transferable. A verification is necessary if the 
analyst or instrument have been changed, or if the sample type has been modified. 
The objective of validation of an analytical method is to demonstrate that the procedure, 
when correctly applied, produces results that are fit for purpose. Method validation is a 
practical process designed and experimentally carried out to ensure that an analytical 
methodology is accurate, specific, reproducible and rugged over the specified range of 
analysis. Validation provides both assurance and reliability during normal use and 
documented evidence that the method is ‘fit for purpose’. The different validation 
parameters are as follows. 
Accuracy: 
It is defined as closeness of agreement between the actual (true) value and mean 
analytical value obtained by applying a test method number of times. Accuracy of an 
analytical method is determined by systematic error involved. The accuracy is 
acceptable if the difference between the true value and mean measured value does not 
exceed the RSD values obtained for repeatability of the method. The parameter 
provides information about the recovery of the drug from sample and effect of matrix, 
as recoveries are likely to be excessive as well as deficient.  
       Accuracy is calculated the percentage recovery by the assay of the known amount 
of analyte in the sample or as the difference between the mean and the accepted true 
value, together with confidence intervals. 
      For assay method, spiked samples are prepared in triplicate at three intervals over 
a range of 50-100% of the target concentration. Potential impurities should be added 
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to the matrix to mimic impure samples. The analyte levels in the spiked samples. The 
analyte levels in the spiked samples should be determined using the same quantitation 
procedure as will be used in the final method procedure (i.e. same levels o standards 
and same number of samples and standard injections).            
Precision: 
The precision of an analytical method is the degree of agreement among individual 
test results when the method is applied repeatedly to multiple sampling of 
homogenous sample. 
Precision is the measure of the degree of repeatability of an analytical method 
under normal operation and is normally expressed as the percent relative standard 
deviation for a statistically significant number of samples. According to the ICH, 
precision should be performed at three different levels: repeatability, intermediate 
precision, and reproducibility.   
               In the case of method precision, six replicates from the same batch are 
analyzed for the assay and dissolution parameters and observing the amount of scatter 
in the results. An example of precision criteria of an assay method is that the 
instrument precision RSD should not be more than 2.0%. Documentation in support 
of precision studies should include the standard deviation, relative standard deviation, 
coefficient of variation, and the confidence interval. 
 
 
Repeatability: 
Repeatability is the results of the method operating over a short time interval under 
the same conditions (inter-assay precision). It should be determined from a minimum 
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of nine determinations covering the specified range of the procedure (for example, 
three levels, three repetitions each) or from a minimum of six determinations at 100% 
of the test or target concentration. 
Intermediate precision: 
Intermediate precision is the results from within lab variations due to random events 
such as different days, analysts, equipment, etc. In determining intermediate 
precision, experimental design should be employed so that the effects (if any) of the 
individual variables can be monitored. 
Reproducibility: 
 Reproducibility refers to the results of collaborative studies between laboratories. 
Specificity: 
It is the ability of an analytical method to assess unequivocally the analyte of interest 
in the presence of components that may be expected to be present, such as impurities, 
degradation products and matrix components. In case of the assay, demonstration of 
specificity requires that the procedure is unaffected by the presence of impurities or 
excipients. In practice, this can be done by spiking the drug substances or product 
with appropriate levels of impurities or excipients and demonstrating that the assay is 
unaffected by the presence of these extraneous materials. 
Limit of Detection: 
The limit of detection (LOD) is defined as the lowest concentration of an analyte in a 
sample that can be detected, not quantitated. It is a limit test that specifies whether or 
not an analyte is above or below a certain value. It is expressed as a concentration at a 
specified signal-to-noise ratio, usually two- or three-to-one. The ICH has recognized 
the signal-to-noise ratio convention, but also lists two other options to determine 
LOD: visual non-instrumental methods and a means of calculating the LOD. Visual 
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non-instrumental methods may include LOD’s determined by techniques such as thin 
layer chromatography (TLC) or titrations. LOD’s may also be calculated based on the 
standard deviation of the response (SD) and the slope of the calibration curve (S) at 
levels approximating the LOD according to the formula: LOD = 3.3(SD/S).  
Limit of Quantitation: 
The Limit of Quantization (LOQ) is defined as the lowest concentration of an analyte 
in a sample that can be determined with acceptable precision and accuracy under the 
stated operational conditions of the method. Like LOD, LOQ is expressed as a 
concentration, with the precision and accuracy of the measurement also reported. 
Sometimes a signal-to-noise ratio of ten-to-one is used to determine LOQ. This 
signal-to-noise ratio is a good rule of thumb, but it should be remembered that the 
determination of LOQ is a compromise between the concentration and the required 
precision and accuracy. That is, as the LOQ concentration level decreases, the 
precision increases. If better precision is required, a higher concentration must be 
reported for LOQ. This compromise is dictated by the analytical method and its 
intended use. The calculation method is again based on the standard deviation of the 
response (SD) and the slope of the calibration curve (S) according to the formula: 
LOQ = 10(SD/S). Again, the standard deviation of the response can be determined 
based on the standard deviation of the blank, on the residual standard deviation of the 
regression line, or the standard deviation of y-intercepts of regression lines. 
Linearity and Range: 
Linearity is the ability of the method to elicit test results that are directly proportional 
to analyte concentration within a given range. Linearity is generally reported as the 
variance of the slope of the regression line. Range is the interval between the upper 
and lower levels of analyte (inclusive) that have been demonstrated to be determined 
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with precision, accuracy and linearity using the method as written. The range is 
normally expressed in the same units as the test results obtained by the method ICH25 
recommended that, for the establishment of linearity, a minimum of five 
concentrations. It is also recommended that the following minimum specified range 
should be considered. For assay of a drug substance or a finished product 80-120% of 
the test concentration should be taken. For an impurity test, the minimum range is 
from the reporting level of each impurity, to 120% of the specification. (For toxic or 
more potent impurities, the range should be commensurate with the controlled level.)          
       Acceptability of the linearity data is often judged by examining the 
correlation co-efficient and y-intercept of the linear regression line for the response 
versus concentration plot. The correlation coefficient of >0.999 is generally 
considered as evidence of acceptable fit of the data to the regression line. The y-
intercept should be less than a few percent of the response obtained for the analyte at 
to target level 
Ruggedness: 
Ruggedness, according to the USP, is the degree of reproducibility of the results 
obtained under a variety of conditions, expressed as %RSD. The ruggedness of an 
analytical method is the degree of reproducibility of test results obtained by the 
analysis of the same samples under a variety of conditions such as different 
laboratories, different analysts, different instruments, different lots of reagents, 
different elapsed assay times, different assay temperatures, different days, etc. 
Robustness: 
Robustness is the capacity of a method to remain unaffected by small deliberate 
variations in method parameters. The robustness of a method is evaluated by varying 
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method parameters such as percent organic, pH, ionic strength, temperature, etc., and 
determining the effect (if any) on the results of the method. 
The robustness of the methods was determined by performing the assay of the 
triplicate by deliberately alternating parameters and that the results are not influenced 
by different changes in the above parameters 
   Change in column temperature + or - 50C 
   Change in flow rate + or -10%. 
   Change in organic phase + or -2%. 
   Change in pH + or -0.2. 
          The system suitability and the precision of the assay were evaluated for the 
respective condition. The robustness of an analytical procedure is the measure of its 
capability to remain unaffected by small, but deliberate, variation in method 
parameters and providers an indication of its reliability during normal usage. 
 
Chromogenic reagents used in the present investigation. 
Functional groups present in organic drugs determine the way of analyzing 
them because they are responsible for the properties of substances and determine the 
identification reaction and the methods of quantitative determination of drugs. 
Knowing the reactions for detecting functional groups, one can easily analyze any 
organic drug with a complicated structure. In the present investigation, few visible 
spectrophotometric methods have been developed for LMV and STV by developing 
colour in each case with, appropriate reagent. The analytically useful functional 
groups in the drug have not been exploited completely in developing the new visible 
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spectrophotometric method and so, the drugs have been selected in the present 
investigation. 
Different type of reagents like Gibbs reagent, MBTH reagent and BPB reagent 
were used in the present investigation for developing visible spectrophotometric 
methods. 
2, 6 Dichloroquinone chlorimide35-36 
2, 6 Dichloroquinone chlorimide was also called as Gibbs reagent. Gibbs reagent 
mainly reacts with phenols, primary amines, secondary amines, aliphatic amines. For 
the present study the reagent was prepared in methanol. 
3-Methyl 2-benzathiozolinone hydrazone37-39 
 MBTH was synthesized by Besthron.  MBTH can react with carbonyl compounds 
and compounds containing amine group. It also forms a strongly electrophilic 
diazonium salt when acted upon by an oxidizing agent. Ferric chloride has been 
mostly used as the oxidizing agent for the determination of amines.  
Bromophenol Blue40-41 
As an acid-base indicator its useful range lies between pH 3.0 and 4.6. It changes 
from yellow at pH 3.0 to purple at pH 4.6; this reaction is reversible. Bromophenol 
blue is structurally related to phenolphthalein. Bromophenol blue is also used as a 
dye. At neutral pH, the dye absorbs red light most strongly and transmits blue light. 
Solutions of the dye therefore are blue. At low pH, the dye absorbs ultraviolet and 
blue light most strongly and appears yellow in solution. In solution at pH 3.6 (in the 
middle of the transition range of this pH indicator) obtained by dissolution in water 
without any pH adjustment, bromophenol blue has a characteristic green red colour. 
This phenomenon is called dichromatic colour. Bromophenol blue is the substance 
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with the highest known value of Kreft's dichromaticity index. This means that it has 
the largest change in colour, when the thickness or concentration of observed sample 
increases or decreases. 
Introduction to Antiretroviral drugs  
Antiretroviral drugs are medications for the treatment of infection 
by retroviruses, primarily HIV. When several such drugs, typically three or four, are 
taken in combination, the approach is known as highly active antiretroviral 
therapy, or HAART. The American National Institutes of Health and other 
organizations recommend offering antiretroviral treatment to all patients with AIDS. 
Because of the complexity of selecting and following a regimen, the severity of the 
side-effects and the importance of compliance to prevent viral resistance, however, 
such organizations emphasize the importance of involving patients in therapy choices, 
and recommend analyzing the risks and the potential benefits to patients without 
symptoms. 
Multiple drugs are used in a single patient, sensitive and specific analytical methods 
are reported for simultaneously determining plasma concentrations42-45 for as many 
HIV drugs. One reported method also reveals simultaneous determination of six 
NRTIs46-48 and nevirapine. However, only one method has been reported till date for 
simultaneous determination of lamivudine, zidovudine and nevirapine in human 
plasma using ion-pair HPLC49.  
The primary objective in the analysis of a antiretroviral drugs is to design and develop 
methods preferably instrumental ones such as UV spectrometric/colorimetric/ HPLC/ 
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GC50-52 that are sensitive and reproducible, when applied for analysis of marketed 
formulations. 
 
Antiretroviral (ARV) drugs are broadly classified by the phase of the retrovirus life-
cycle that the drug inhibits. 
[1] Nucleoside and nucleotide reverse transcriptase inhibitors (NRTI) inhibit 
reverse transcription by being incorporated into the newly synthesized viral DNA 
and preventing its further elongation. 
[2] Non-nucleoside reverse transcriptase inhibitors (NNRTI) inhibit reverse 
transcriptase directly by binding to the enzyme and interfering with its function. 
[3] Protease inhibitors (PIs) target viral assembly by inhibiting the activity 
of protease, an enzyme used by HIV to cleave nascent proteins for final assembly 
of new virons. 
[4] Integrase inhibitors inhibit the enzyme integrase, which is responsible 
for integration of viral DNA into the DNA of the infected cell. There are several 
integrase inhibitors currently under clinical trial, andraltegravir became the first to 
receive FDA approval in October 2007. 
[5] Entry inhibitors (or fusion inhibitors) interfere with binding, fusion and entry 
of HIV-1 to the host cell by blocking one of several 
targets. Maraviroc and enfuvirtide are the two currently available agents in this 
class. 
[6] Maturation inhibitors inhibit the last step in gag processing in which the viral 
capsid polyprotein is cleaved, thereby blocking the conversion of the polyprotein 
21 
 
into the mature capsid protein. Because these viral particles have a defective core, 
the virions released consist mainly of non-infectious particles. There are no drugs 
in this class currently available, though two are under 
investigation, bevirimat and Vivecon. 
[7] AV-HALTs (Anti Viral Hyper Activation Limiting Therapeutics or 
'virostatics') combine immune modulating and antiviral properties to inhibit a 
specific antiviral target while also limiting the hyper-elevated state of immune 
system activation driving disease progression.  
[8] Broad spectrum inhibitors. Some natural antiviral, such as extracts from 
certain species of mushrooms like Shiitake and Oyster mushrooms, may contain 
multiple pharmacologically active compounds, which inhibit the virus at various 
different stages in its life cycle. Researchers have also isolated a protease inhibitor 
from the Shiitake mushroom.  
1.4 Formulae for calculations 
a) Coefficient of variation (%COV) = S x 100 / X    
b) Tailing factor (Tf) = W0.05 / 2f   
c) Theoretical plates (N) = 5.54(t/w) 
d) % area difference = 100
Ai
AiAf
 
e) Detection Limit (DOL) = 
S
F3.3
  
f) Quantitation Limit (LOQ) = 
S
F10
 
g) In Accuracy: 
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      i) mg actually added (A) = 
100
PW 
 
     ii) mg found in spiked sample (F) = TWP
W
D
D
W
spl
spl
std
spl 
100A
A
 
std
spl
 
   
 iii) mg recovered (R) =    SF 
 
    
iv) % recovered =   
A
R 100
  
h) Simultaneous equations 
 
                         CX =     (A2ay1-A1ay2)  
                
                                              (ax2ay1 - ax1ay2) 
 
                                  CY =     (A2ay1-A1ay2)  
         
                                              (ax2ay1 - ax1ay2) 
 
Where, 
Aspl = Average area response of LMV/ZVD/NVP in sample solution 
Astd = Average area response of LMV/ZVD/NVP in standard solution 
Wstd/spl = Weight of LMV/ZVD/NVP standard/sample in mg 
DS = Dilution of standard  
D
 std/spl = Dilution of sample 
P = Potency of LMV/ZVD/NVP Standard (%w/w, on as is basis) 
LC = Label claim of E 
AW = Average weight 
Tf = Peak asymmetry or tailing factor 
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W0.05 = Distance from the leading edge to the tailing edge of the peak measured at a 
point  
            5 % of the peak height from the baseline 
f = Distance from the peak maximum to the leading edge of the peak 
t = Retention time (min) 
w = Width at the half height 
Af = Final area 
Ai = Initial area 
F = Standard deviation of the response 
S = Slope of the calibration curve 
W = Weight of standard 
 P = Potency of standard  
F-S = mg found in spiked sample - mg present in sample as such 
TW = Theoretical weight of sample 
R= mg recovered 
A = mg actually added 
X= Mean 
 S = Standard deviation   
Cx = Concentration of lamivudine  
 Cy = Concentration of zidovudine  
ax1 and ax2 = Absorptivity of lamivudine at 271.1nm and 264 nm 
ay1 and ay2 =Absorptivity of zidovudine at 271.1nm and 264 nm 
 A1= Absorbance of lamivudine at 271.1nm 
 A2= Absorbance of lamivudine at 264 nm 
 
24 
 
 2. OBJECTIVES 
 Develop new, simple, sensitive, accurate, and economical analytical 
method for the determination of Lamivudine, Zidovudine and 
Nevirapine by HPLC, and validate the proposed method.  
 Develop new, simple, sensitive, accurate, and economical analytical 
method for the determination of Lamivudine by GC, and validate the 
proposed method. 
 Develop few simple, sensitive UV spectrometric/colorimetric methods 
for the determination of antiretroviral drugs and validate the developed 
methods.   
Lamivudine, zidovudine and nevirapine is a relatively new 
combination. Since multiple drugs are used in a single patient, sensitive and 
specific analytical methods are needed for simultaneously determining plasma 
concentrations for as many HIV medications as possible. Till date, numerous 
analytical methods have been reported for the quantitative determination of 
lamivudine, zidovudine or nevirapine alone or in combination with other 
antiviral drugs. One reported method also reveals simultaneous determination 
of six NRTIs and nevirapine. However, only one method has been reported till 
date for simultaneous determination of lamivudine, zidovudine and nevirapine 
in human plasma using ion-pair HPLC.  
The primary objective in the analysis of antiretroviral drugs is to design and 
develop methods preferably instrumental ones such as UV 
spectrometric/colorimetric/ HPLC/ GC that are sensitive and reproducible, 
when applied for analysis of marketed formulations. 
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  3. REVIEW OF LITERATURE 
The following methods have been reported for the estimation of LMV, ZVD, EFZ, 
STV and NEV individually and in combination with other drugs. 
3.1 Lamivudine (LMV):  
N
N
NH2
O
S
O
HO
 
Molecular formula: C8 H11N3O3S 
Molecular mass: 229.26 g/mol 
Melting point: 175˚C 
IUPAC name : 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-
dihydropyrimidin-2-one 
Physicochemical properties: 
 It is a white crystalline powder 
 soluble in methanol and water 
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Brand Names: 
 Lamivir 
 Lamidac 
Drug Category: 
 Anti-HIV Agents 
 Nucleoside Reverse Transcriptase Inhibitors 
 Reverse Transcriptase Inhibitors 
 Reverse transcriptase of hepatitis b Inhibitors 
Pharmacology: 
Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of HIV reverse 
transcriptase and also the reverse transcriptase of hepatitis B. It needs to be 
phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits 
cellular DNA polymerase. 
Basavaiah K54 et al developed a titrimetric and spectrophotometric method for the 
determination of LMV  in bulk and tablet dosage form using chloramine-T and two 
dyes, methyl orange and indigo carmine as reagents. The unreacted oxidant is 
determined iodometrically. In the spectrophotometric method lamivudine was 
measured at 610nm. The linearity range was found to be at 3 to 10 ȝg/ml and 0.35 to 
3.0 ȝg/ml. 
Jayaseelan S55 et al developed and validated a Bioanalytical method for the 
estimation of LMV by RP-HPLC with UV detection was developed and validated to 
separate and detect lamivudine in human plasma using Stavudine as an internal 
standard. LMV and STV were extracted from human plasma using methanol protein 
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precipitation and were chromatographed on a Phenomenex C18 (250X4.6mm, 5mȝ 
particle size) column using 20ȝl injection volume and detection at 270 nm. An 
isocratic mobile phase consisting of Methanol: Water (85:15%v/v) was used.  
Devyani Dube56 et al carried out the simultaneous spectrophotometric estimation of 
LMV and Silymarin in mixture. The method employs formation and solving of 
simultaneous equation using 270.9 nm and 326.4 nm as two analytical wavelengths. 
Both the drugs obey Beer’s Law in the concentration ranges employed for this 
method. 
Sockalingam57 et al done the simultaneous quantification of stavudine, lamivudine 
and nevirapine by UV spectroscopy, reverse phase HPLC and HPTLC in tablets. In 
the UV multi-component spectral method, STV, LMV and NVP was quantified at 
266, 271 and 315 nm, respectively. The retention time of STV, LMV and NVP was 
2.85, 4.33 and 8.39 min, respectively. In the HPTLC method, the chromatograms 
were developed using a mobile phase of chloroform: methanol (9:1, v/v).  
 
Bin Fan58 et al developed a new high-performance liquid chromatography (HPLC) 
assay was developed for the simultaneous determination of zidovudine, LMV and 
NVP in human plasma. Plasma samples were treated using a solid-phase extraction 
procedure. The compounds were separated using a mobile phase of 20 mM sodium 
phosphate buffer (containing 8 mM 1-octanesulfonic acid sodium salt)–acetonitrile 
(86:14, v/v) with pH adjusted to 3.2 with phosphoric acid on an octylsilane column 
(150×3.9 mm i.d.) with UV detection at 265 nm.  
Abd El-Maaboud59
 
et al developed a simple chemometrics-assisted 
spectrophotometric method for the simultaneous determination of LMV and STV in 
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pharmaceutical tablets is described. The UV absorption spectra of the studied drugs, 
in the range of 200–310 nm, showed a considerable degree of spectral overlapping 
([Di] 0.5 = 94.9%). Beer’s law was obeyed for both drugs in the general concentration 
ranges of 2–12 and 3–15 ȝg/ml for LMV and STV, respectively.
 
3.2 Stavudine (STV): 
NH
N
O
O CH3
O
OH
   STV
 
Molecular formula: C10H12N2O4  
Molecular mass: 224.213 g/mol 
Melting point: 160˚C 
 IUPAC name: 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-
1,2,3,4-tetrahydropyrimidine-2,4-dione 
Physicochemical properties: 
 Soluble in water, methanol & chloroform 
Brand Names: 
 Virostav 
 Stag 
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Drug Category: 
 Anti-HIV Agents 
 
 Pharmacology: 
Stavudine is an analog of thymidine. It is phosphorylated by cellular kinases into 
active triphosphate. Stavudine triphosphate inhibits the HIV reverse transcriptase by 
competing with natural substrate, thymidine triphosphate. It also causes termination 
of DNA synthesis by incorporating into it. Simultaneous use of LMV is not 
recommended, as it can inhibit the intracellular phosphorylation of stavudine. Other 
anti-HIV drugs do not possess this property. The oral absorption rate of stavudine is 
over 80%. Approximately half of stavudine is actively secreted unchanged into the 
urine and the other half is eliminated through endogenic pathways.  
Basavaiah K60 et al carried out the rapid titrimetric and spectrophotometric methods 
for the determination of stavudine in pharmaceuticals using bromate-bromide and 
three dyes. In titrimetry, aqueous solution of STV was treated with a known excess of 
bromate-bromide in HCl medium followed by estimation of unreacted bromine by 
iodometric back titration. Spectrophotometric methods involve the addition of a 
measured excess of bromate-bromide in HCl medium and subsequent estimation of 
the residual bromine by reacting with a fixed amount of methyl orange, indigocarmine 
or thymol blue followed by measurement of absorbance at 520 nm (method A), 610 
nm (method B) or 550 nm (method C).  
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Namita Kapoor61 et al described two methods for the simultaneous determination of 
lamivudine and stavudine in combined pharmaceutical tablets. The first method 
depends on first derivative UV-spectrophotometry with zero-crossing measurement 
technique. The first derivative absorbances at 280 and 300 nm were selected for the 
determination of stavudine and lamivudine, respectively. The second method is based 
on the separation of both drugs by high performance liquid chromatography using 
methanol: water (20:80) as the mobile phase at 0.6 ml/min on a reverse phase column 
with detection at 270 nm.  
C.P.W.G.M. Verweij-van Wissen62 et al developed a reversed phase RP-HPLC 
method for the simultaneous quantitative determination of the nucleoside reverse 
transcriptase inhibitors (NRTIs) lamivudine, didanosine, stavudine, zidovudine and 
abacavir in plasma. The method involved solid-phase extraction with Oasis MAX 
cartridges from plasma, followed by HPLC with a RP C-18 column and UV detection 
set at a wavelength of 260 nm. The assay was validated over the concentration range 
of 0.015–5 mg/l for all five NRTIs.  
Marı́a Sarasa63 et al reported a Sensitive HPLC method for the quantification 
of STV in human plasma and urine. The methods are linear over the concentration 
ranges 0.025–25 ȝg/ml and 2–150 ȝg/ml in plasma and urine, respectively. An aliquot 
of 200 ȝl of plasma was extracted with solid-phase extraction using Oasis cartridges, 
while urine samples were simply diluted 1/100 with HPLC water. The detection limit 
is 12 ng/ml in plasma for a sample size of 200 ȝl.  
Ashenafi Dunge64 et al developed a validated stability-indicating HPLC assay 
method The drug was found to hydrolyze in acidic, neutral and alkaline conditions 
and also under oxidative stress. The major degradation product formed under various 
conditions was thymine, as evidenced through comparison with the standard and 
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spectral studies (NMR, IR and MS) on the isolated product. Separation of drug, 
thymine and another minor degradation product was successfully achieved on a C-18 
column utilizing water–methanol in the ratio of 90:10. The detection wavelength was 
265 nm.  
3.3 Zidovudine (ZVD): 
N
NH
O
O
O
H3C
HO
NN-+N
 
Molecular formula: C10H13N5O4 
Molecular mass: 267.242 g/mol 
Melting point: 116 ˚C 
IUPAC name: 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-
1,2,3,4-tetrahydropyrimidine-2,4-dione 
Physicochemical properties: 
 White crystalline powder 
 Soluble in water and methanol  
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Brand Names: 
 Zidovir 
 Zidomax  
 
Drug Category: 
 Anti-HIV Agents 
 Nucleoside Reverse Transcriptase Inhibitors 
Pharmacology: 
Like other reverse transcriptase inhibitors, ZVD works by inhibiting the action 
of reverse transcriptase, the enzyme that HIV uses to make a DNA copy of its RNA. 
Reverse transcription is necessary for production of the viral double-stranded DNA, 
which is subsequently integrated into the genetic material of the infected. The azido 
group increases the lipophilic nature of ZVD, allowing it to cross cell 
membranes easily by diffusion and thereby also to cross the blood-brain barrier.  
K Basavaia65 et al developed Spectrophotometric Methods for the Determination of 
Zidovudine in Pharmaceuticals Using Chloramine-T, Methylene Blue and 
Rhodamine-B as Reagents. The methods use chloramine-T (CAT) and two dyes, 
methylene blue and rhodamine-B, as reagents and are based on adding of a known 
excess of CAT to ZVD in hydrochloric acid medium followed by determination of 
residual oxidant by reacting with a fixed amount of either methylene blue and 
measuring the absorbance at 665 nm (Method A) or rhodamine B and measuring the 
absorbance at 555 nm (Method B). In both methods, the amount of CAT reacted 
corresponds to the amount of ZVD. The absorbance measured is found to increase 
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linearly with concentration of ZVD. Under the optimum conditions, ZVD could be 
assayed in the concentration range 1.25-15.0 and 0.25-3.0 mg/ml by method A and 
method B, respectively. 
Vaishali P. Nagulwar66 et al developed a validated UV spectrophotometric method 
for the simultaneous estimation of LMV, NVP and ZVD in combined tablet dosage 
form. The stock solutions were prepared in 0.5M HCl followed by the further required 
dilutions with distilled water. The lmax for lamivudine, nevirapine and zidovudine 
were 280.2 nm, 312 nm and 266.8 nm respectively. Linearity in concentration range 
of 5-25 mg/ml, 5-50 mg/ml and 5-40 mg/mL was shown respectively by the three 
drugs.  
 
Anantha kumar .D67 et al reported a simultaneous determination of LMV, ZVD and 
Abacavir in Tablet Dosage Forms by RP HPLC Method. Chromatography was carried 
out on a HiQ Sil C 18 column using a mobile phase consisting of 0.01 M potassium 
dihydrogen ortho-phosphate (pH 3.0) and methanol (55:45 v/v) at a flow rate of 0.8 
ml/min. The detection was made at 272 nm and stavudine was used as the internal 
standard for this study. The retention times for lamivudine, abacavir and zidovudine 
were found to be 3.8, 6.3, 8.1 min. respectively. The calibration curves were linear 
over the range 5-250 ȝg/ml for both zidovudine and abacavir and 5-140 ȝg/ml for 
lamivudine. 
Vibhuti Kabra68
 
et al developed the simultaneous quantitative determination of 
zidovudine and nevirapine in human plasma using isocratic, reverse phase high 
performance liquid chromatography. In the HPLC measurement, sample detection 
was carried out at 246 nm using an ultraviolet (UV) photo diode array (PDA) detector 
The compounds were separated using a mobile phase consisting of a pH 3.0 solution 
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(obtained by adjusting the pH of water with orthophosphoric acid): acetonitrile (73:27 
v/v) on a Phenomenex LUNA C18, column (250×4.6 mm i.d., 5ȝm) at a flow rate of 
0.9 ml/min. The total run time for the assay was 10.2 min. The method was validated 
over the range of 300-9600 ng/ml and 200-6400 ng/ml for ZVD and NVP, 
respectively. 
 
3.4 Nevirapine (NVP): 
N
NH
O
N N
 
Molecular formula: C15H14N4O  
Molecular mass: 266.298 g/mol 
Melting point: 247 ˚C 
IUPAC name: 11-cyclopropyl-4-methyl-5,11-dihydro-6H- dipyrido[3,2-b:2′,3′-
e][1,4]diazepin-6-one 
Physicochemical properties: 
 White crystalline powder 
 Soluble in chloroform and methanol  
 
35 
 
Brand Names: 
 Nevivir 
 Nevimune  
Drug Category: 
 Anti-HIV Agents 
 Non-Nucleoside Reverse Transcriptase Inhibitors 
Pharmacology: 
Nevirapine falls in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class 
of antiretrovirals. Both nucleoside and non-nucleoside RTIs inhibit the same target, 
the reverse transcriptase enzyme, an essential viral enzyme which transcribes viral 
RNA into DNA. Unlike nucleoside RTIs, which bind at the enzyme's active site, 
NNRTIs bind allosterically at a distinct site away from the active site termed the 
NNRTI pocket. Resistance to nevirapine develops rapidly if viral replication is not 
completely suppressed. As all NNRTIs bind within the same pocket, viral strains 
which are resistant to nevirapine are usually also resistant to the other 
NNRTIs, efavirenz and delavirdine.  
Purnima Hamrapurkar69 et al developed a RP-HPLC with ultraviolet detection has 
been developed and validated for the estimation of nevirapine from human plasma. 
Chromatographic separation was achieved on Waters RP C18 10 ȝm column having 
250 × 4.6 mm ID with a mobile phase containing 15 mM aqueous phosphate buffer: 
acetonitrile (65:35 % v/v) in isocratic mode. The flow rate was 1.0 ml / min and 
effluents were monitored at 283 nm. The retention time of nevirapine and the internal 
standard was 5.1 min and 6.2 min respectively. 
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Purnima70
 
et al developed a HPTLC method for the estimation of nevirapine from 
bulk drug and tablet formulations. The separation was achieved on TLC plates using 
appropriate solvent system. The spots so developed were densometrically scanned at 
283 nm. The linearity of the method was found to be within the concentration range of 
2.50ȝg/ml to 62.50ȝg/ml. 
Wenjing Chen71
 
et al developed a high-performance analytical method based on 
capillary electrophoresis to investigate interactions between HIV RT (reverse 
transcriptase enzyme) and NVP was developed Samples containing HIV RT 
and NVP at various ratios were incubated at 37 °C for 45 min and then separated by 
CE with Tris–acetate buffer at pH 7.3 containing 0.15% SDS.  The binding constants 
of the interactions between HIV RT and NVP were calculated as 
(3.25 ± 0.16) × 104 and (1.25 ± 0.07) × 102 M−1 by Scatchard analysis. HIV RT 
and NVP have two binding sites.  
Peter Langmann72
 
et al reported a sensitive and rapid gas 
chromatographic method to determine the levels of the HIV-1 non-nucleoside reverse 
transcriptase inhibitor NVP in human plasma. Quantitative recovery following liquid–
liquid-extraction with diethyl ether from 500 ȝl of human plasma was achieved. 
Subsequently, the assay was performed with a CP-Sil 5CB capillary column, 15 
m×0.32 mm×1.0 ȝm film thickness with a nitrogen–phosphorous-detector (NPD), 
Helium 5.0 was used as carrier gas with a constant inlet pressure of 7 psi. Linear 
standard curves were obtained for concentrations ranging from 10 to 20 000 ng/ml.  
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3.5 Efavirenz (EFZ): 
O
H
N
Cl
F
F
F
O
 
Molecular formula: C14H9ClF3NO2 
Molecular mass: 315.675 g/mol 
IUPAC name: (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-
dihydro-1H-3,1-benzoxazin-2-one 
Physicochemical properties: 
 White crystalline powder 
 Soluble in methanol and insoluble in water 
Brand Names: 
 Efavir 
 Estiva 
Drug Category: 
 Anti-HIV Agents 
 Non-Nucleoside Reverse Transcriptase Inhibitors 
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Pharmacology: 
Efavirenz falls in the NNRTI class of antiretrovirals. Both nucleoside and non-
nucleoside RTIs inhibit the same target, the reverse transcriptase enzyme, an essential 
viral enzyme which transcribes viral RNA into DNA. Unlike nucleoside RTIs, which 
bind at the enzyme's active site, NNRTIs act allosterically by binding to a distinct site 
away from the active site known as the NNRTI pocket. Efavirenz is not effective 
against HIV-2, as the pocket of the HIV-2 reverse transcriptase has a different 
structure, which confers intrinsic resistance to the NNRTI class. As most NNRTIs 
bind within the same pocket, viral strains which are resistant to efavirenz are usually 
also resistant to the other NNRTIs, nevirapine and delavirdine.
 
Deshpande Anant73 et al developed a simple, sensitive and accurate 
spectrophotometric method was developed in ultraviolet region for the estimation of 
efavirenz (EFZ) in pure drug, pharmaceutical formulation. Linear response obtained 
was in the concentration range of 5-40 µg/ml with correlation coefficient of 0.9993, 
0.9989 in solvent and plasma respectively. Excellent recovery proved that the method 
was sufficiently accurate.  
Anri Theron74
 
et al reported a novel and robust screening method for the 
determination of the non-nucleoside reverse transcriptase inhibitor, EFZ, in human 
saliva and validated based on tandem mass spectrometry (LC–MS/MS). The analytes 
were separated by high performance liquid chromatography (Phenomenex Kinetex 
C18, 150 mm × 3 mm internal diameter, 2.6 ȝm particle size) and detected with 
tandem mass spectrometry in electrospray positive ionization mode with multiple 
reaction monitoring. Gradient elution with increasing methanol concentration was 
used to elute the analytes, at a flow-rate of 0.4 ml/min. The total run time was 8.4 min 
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and the retention times for the internal standard (reserpine) was 5.4 min and for EFZ 
was 6.5 min.  
Geetha Ramachandran75 et al reported a simple and rapid high performance liquid 
chromatographic method for determination of EFZ in human plasma. The method 
involved extraction of sample with ethyl acetate and analysis using a reversed-phase 
C18 column (150 mm) with UV detection. The assay was linear from 0.0625 to 
10.0 ȝg/ml. The method was specific for EFZ estimation and the drug was stable in 
plasma up to one month at −20 °C. The average recovery of EFZ from plasma was 
101%. Due to its simplicity, the assay can be used for pharmacokinetic studies and 
therapeutic drug monitoring of EFZ.   
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4. MATERIALS AND METHODS 
PART A: UV-VISIBLE SPECTROPHOTOMETRIC METHODS FOR 
LMV AND STV 
Method 1: Estimation of lamivudine by MBTH reagent  
Method 2: Estimation of lamivudine by Bromophenol blue dye   
Method 3: Estimation of stavudine by selective oxidation using Cerium (IV) 
ammonium sulphate regent 
Method 4: Estimation of stavudine by 2, 6-Dichloroquinone Chlorimide 
(Gibb’s regent)  
PART B: SIMULTANEOUS ESTIMATION OF LAMIVUDINE, 
ZIDOVUDINE AND EFAVIRENZ BY UV- SPECTROPHOTOMETRY 
Method 5: By Three wavelength spectrophotometry 
PART C: RP-HPLC METHOD 
Method 6: Simultaneous estimation of lamivudine, Zidovudine and 
Nevirapine  
 
PART D: GC METHOD  
Method 7: Estimation of Lamivudine by Gas Chromatographic method using 
Ethyl Chloroformate as a Derivatizing reagent  
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            PART A: UV- VISIBLE SPECTROPHOTOMERTIC METHODS 
Method 1: ESTIMATION OF LAMIVUDINE BY MBTH REAGENT 
1.1 PRINCIPLE INVOLVED 
The principle is based on the oxidation followed by coupling of 3-methyl-2-
benzothiazolinone hydrazone with LMV in the presence of ferric chloride to 
form a green colored chromogen. This is an ion catalyzed oxidative coupling 
reaction of MBTH with the drug. Under reaction conditions, on oxidation, 
MBTH loses two electrons and one proton forming an electrophilic 
intermediate, which is the active coupling agent. This intermediate undergoes 
electrophilic substitution with the drug to form the colored product (Scheme 
1). 
1.2 REACTION INVOLVED –  
N
S
N
CH3
NH2 + FeCl3
N
S
N
CH3
NH+
-H+ -2e
Drug
N
S
CH3
N N
N
NO
S
O
NH
HO
Green colored chromogen
MBTH
 
Scheme 1: Reaction pathway between Lamuvidine and MBTH reagent. 
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1.3 PREPARATION OF REAGENTS 
1.3.1 MBTH (0.5% w/v) 
0.5 g of MBTH was weighed accurately and dissolved in distilled water in 100 
ml volumetric flask and volume was made up to mark with water  and filtered. 
1.3.2 Ferric chloride (1% w/v) 
1 g of Ferric chloride was weighed accurately and dissolved in distilled water 
in 100 ml volumetric flask and volume was made up to mark with water  and 
filtered. 
1.4 PREPARATION OF STANDARD CALIBRATION CURVE  
1.4.1 Preparation of standard stock solution 
Accurately weighed 10.0 mg of lamivudine (bulk drug) was dissolved in 40.0 
ml of warm distilled water in 100 ml volumetric flask and sonicated for about 
15 min to enhance the solubility and volume was made up to the mark with 
distilled water to obtain a concentration of 100 µg/ml. 
1.4.2 Preparation of calibration curve 
Varying aliquots (0.1–0.7 ml) of the standard 100 ȝg/ml LMV solutions were 
transferred into a series of 10 ml calibrated flasks by means of a micro burette. 
To all the calibrated 10 ml flasks, 1 ml of 0.5% MBTH reagent was added. 
The solutions were swirled and allowed to stand for 5 min. A 1 ml of 1% 
FeCl3 solution is added to all the flasks, the solutions were swirled and 
allowed to stand     the absorbance was measured at 659 nm against the 
corresponding reagent blank. The calibration curve was constructed by 
plotting absorbance against the initial concentration of LMV. The linearity 
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range or Beer’s range follows in the range between 1 to 8 µg/ml (Fig.1). The 
content of LMV was calculated from the calibration graph. 
1.5 ANALYSIS OF TABLET DOSAGE FORM 
Ten tablets are taken and finely powdered, each claimed to contain 100 mg 
(Lamivir). An amount of the powder equivalent to 100 mg of active 
component was weighed into a 100 ml volumetric flask; about 60 ml of water 
was added and shaken thoroughly for about 20 min. The volume was made up 
to the mark with double distilled water, shaken and filtered using filter paper. 
The filtrate was diluted sequentially to get 0.1 mg/ml of the drug. The 
resultant solution is also analysed as per the procedure and were statically 
validated. 
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Fig.1: Calibration curve for LMV method 1 
 
Fig. 2: Effect of MBTH and FeCl3 on the reaction with LMV. 
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Method 2: ESTIMATION OF LAMIVUDINE BY BROMOPHENOL 
BLUE DYE 
2.1 PRINCIPLE INVOLVED 
The principle is based on the application of acidic dyes for the 
spectrophotometric determination of LMV. The structural formula of LMV 
feature amine group, suggests the use of acidic dyes (BPB) as chromogenic 
reagents (scheme 2). The acid dye technique is a general procedure for the 
quantitative analysis of a variety of pharmaceutical amines. In practice, an 
aqueous solution containing the amine and a suitable indicator dye is shaken 
with an organic solvent. The concentration of the resulting ion-pair is then 
determined spectrophotometrically.  
2.2 REACTION INVOLVED  
N
N
NH2
O
S
O
HO
+
O
S
O
O Br
OH
Br
OH
BrBr
LMV
N
N
NH2
O
S
O
HO
+
SO3
- Br
OH
Br
OH
BrBr
BPB
Ion-pair complex
 
Scheme 2: Reaction pathway between Lamuvidine and BPB dye. 
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2.3 REAGENTS USED 
2.3.1 Bromophenol blue (0.1%) (w/v) 
 0.1 g of BPB was weighed accurately and dissolved in methanol in 100 ml 
volumetric flask and volume was made up to mark with methanol and filtering 
through a Whattman filter paper. 
2.4 PREPARATION OF STANDARD CALIBRATION CURVE  
2.4.1 Preparation of standard stock solution 
Accurately weighed 10.0 mg of lamivudine (bulk drug) was dissolved in 40.0 
ml of methanol in 100 ml volumetric flask and sonicated for about 15 min to 
enhance the solubility and volume was made up to the mark with methanol i.e. 
100 µg/ml. 
2.4.2 Preparation of calibration curve 
Different aliquots (0.1–0.5 ml) of the standard 100 ȝg/ml LMV solution were 
transferred into a series of 10 ml calibrated flasks by means of a micro burette. 
To all the calibrated flasks, 1 ml of 0.1% methanolic solution of BPB was 
added. The solutions were swirled and allowed to stand for 5 min and the 
volume was diluted to the mark with methanol and mixed well. The 
absorbance was measured at 595 nm against the corresponding reagent blank 
and calibration graph was constructed. The calibration curve was constructed 
by plotting absorbance against the initial concentration of LMV. The linearity 
range or Beer’s range follows in the range between 1 to 8 µg/ml (Fig.3). The 
content of LMV was calculated from the calibration graph. 
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2.5 ANALYSIS OF TABLET DOSAGE FORM 
Ten tablets are taken and finely powdered, each claimed to contain 100 mg 
(Lamivir).  An amount of the powder equivalent to 100 mg of active 
component was weighed into a 100 ml volumetric flask; about 60 ml of 
methanol was added and shaken thoroughly for about 20 min. The volume was 
made up to the mark with methanol, shaken and filtered using filter paper. The 
filtrate was diluted sequentially to get 0.1 mg/ml of the drug. The resultant 
solution is also analysed as per the procedure and were statically validated.  
 
Fig. 3: Calibration curve for LMV method 2 
 
 
 
48 
 
 
Fig. 4: Absorbance spectra of (LMV-BPB) and (LMV-MBTH) reaction 
products (initial concentration of LMV was 10 ȝg/ml). 
 
          Fig. 5: Effect of time on the reaction of BPB with LMV. 
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Method 3: ESTIMATION OF STAVUDINE BY SELECTIVE 
OXIDATION USING CERIUM (IV) AMMONIUM SULPHATE 
3.1 PRINCIPLE INVOLVED 
Cerium (IV) and iron (III) ammonium sulphates are strong oxidizing agents 
and are utilized extensively for the determination of organic compounds. 
When stavudine reacts with Cerium (IV) ammonium sulphate it results in the 
formation of a oxidized product (Scheme 3) which can be quantified 
spectrophotometrically. 
3.2 REACTION INVOLVED  
N
HN
O CH3
O
HO
O
+ Ce+4 N
HN
O
O
O
O
+ 2Ce+3
Oxidized productSTV
 
Scheme 3: Reaction pathway between Stavudine and cerium (IV) ammonium 
sulphate. 
3.3 REAGENTS USED 
3.3.1 Perchloric acid 4M 
33.3 ml of perchloric acid (12M)  was accurately taken and diluted in distilled 
water in 100 ml volumetric flask and volume was made up to the mark with 
distilled water.  
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3.3.2 Cerium (IV) ammonium sulphate 0.1% (w/v) 
0.1 g of Cerium ammonium sulphate was weighed accurately and dissolved in 
4 M perchloric acid in 100 ml volumetric flask and then the volume was made 
up to mark with 4 M perchloric acid. 
3.4 PREPARATION OF STANDARD CALIBRATION CURVE  
3.4.1 Preparation of standard stock solution 
Accurately weighed 100.0 mg of STV (bulk drug) was dissolved in 10.0 ml of 
methanol in 100 ml volumetric flask and sonicated for about 15 min to 
enhance the solubility and volume was made up to the mark with double 
distilled water i.e. 1.0 mg/ml (Stock solution A). 
From the above stock solution A 10 ml of aliquot was pipette out in 100 ml 
volumetric flask and the volume was made up to the mark with double 
distilled water to obtain the final concentration of 100 µg/ml (Stock solution 
B). 
3.4.2 Preparation of calibration curve 
Aliquot volumes of standard stock solutions, containing 0.2-1 ml (2-10 µg/ml) 
drug, were transferred to 10 ml calibrated flasks. 1 ml of 4 M perchloric acid 
was added each flask followed by 1.0 ml of Ce (IV) solution, mixed well and 
made up to the mark with distilled water. The absorbance of the resulting 
solutions was measured after 5 min at 282 nm (Fig.6) at 25.5°C against 
reagent blanks treated similarly. The amount of STV present in the sample 
solution was computed from its calibration curve. The linearity range or 
Beer’s range follows in the range between 2-10 µg/ml. The content of STV 
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was calculated either from the calibration graph or corresponding regression 
equation  
3.5 ANALYSIS OF TABLET DOSAGE FORM 
Ten tablets are taken and finely powdered claimed to contain 30 mg (Stadine). 
The accurate quantity of powder equivalent to 100mg of active ingredient was 
dissolved in 10 ml of methanol later diluted with 50 ml of distilled water and 
shaken thoroughly for about 5 min. The volume was made up to the mark with 
distilled water and filtered using Whattman filter paper (Stock solution A). 
From the above stock solution 10.0ml was pipetted out in 100.0ml volumetric 
flask and the volume was made up to the mark with warm double distilled 
water to obtain the final concentration of  100 µg/ml (Stock solution B). From 
the stock solution B 0.5ml of solution is pipetted in to a 10.0ml volumetric 
flask and then the resultant solution is also analysed as per the procedure and 
was validated.  
 
Fig. 6: The graph showing the maximum absorbance for method 3 
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Method 4: ESTIMATION OF STAVUDINE BY 2, 6-
DICHLOROQUINONE CHLORIMIDE OR GIBB’S REGENT 
4.1 PRINCIPLE INVOLVED 
The principal involved is Gibb’s reagent mainly reacts with phenols, primary 
amines, secondary amines, and aliphatic amines to form a colored complex. 
The first step of reaction is formation of the corresponding quinine imines. 
Quinone imines are condensation products of quinone chlorimines with 
phenols in aqueous alkaline media. Imide portion of Gibb’s reagent reacts with 
phenolic compounds gives corresponding products. STV possesses different 
functional groups such as hydroxyl group and amino group. An attempt has 
been made to determine STV by reacting at the Gibb’s reagent.  
4.2 REACTION INVOLVED  
NH
N
O
O
O
NCl
ClCl N O
Cl
Cl
yellow color complex
O
OH
+
NH
N
O
O
O
OH
Gibb's reagent   STV
 
Scheme 4: Reaction pathway between stavudine and Gibb’s reagent. 
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4.3 REAGENTS USED 
4.3.1 2, 6-Dichloroquinone Chlorimide or Gibb’s regent 0.5% (w/v) 
0.5 g of Gibb’s reagent was accurately weighed transferred into a 100 ml 
calibrated volumetric flask and diluted to the mark with Isopropanol 
4.4 PREPARATION OF STANDARD CALIBRATION CURVE  
4.4.1 Preparation of standard stock solution 
Accurately weighed 100.0 mg of STV (bulk drug) was dissolved in 10.0ml of 
methanol in 100ml volumetric flask and sonicated for about 15min to enhance 
the solubility and volume was made up to the mark with double distilled water 
i.e. 1.0 mg/ml (Stock solution A). 
From the above stock solution-A 10 ml of aliquot was pipette out in 100 ml 
volumetric flask and the volume was made up to the mark with distilled water 
to obtain the final concentration of 100 µg/ml (Stock solution B). 
4.4.2 Preparation of calibration curve 
Aliquots of STV ranging from 0.1- 1.2 ml (2.0- 12 µg/ml) were pipette into as 
series of 10 ml volumetric flask. To each flask, 1ml of Gibb’s reagent was 
added to each volumetric flask and made up to the volume with distilled water. 
The absorbance was measured at 528 nm (Fig.7) against a reagent blank. The 
amount of STV present in the sample solution was computed from its 
calibration curve. The calibration curve was constructed by plotting 
absorbance against the initial concentration of STV. The linearity range or 
Beer’s range follows in the range between 2.0-12 µg/ml. The content of STV 
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was calculated either from the calibration graph or corresponding regression 
equation. 
 
4.5 ANALYSIS OF TABLET DOSAGE FORM 
Ten tablets are taken and finely powdered claimed to contain 30 mg (Stadine). 
The accurate quantity of powder equivalent to 100 mg of active ingredient was 
dissolved in 10 ml of methanol later diluted with 50 ml of distilled water and 
shaken thoroughly for about 5 min. The volume was made up to the mark with 
distilled water and filtered using whattman filter paper (Stock solution A). 
From the above stock solution 10.0 ml was pipetted out in 100.0 ml 
volumetric flask and the volume was made up to the mark with warm double 
distilled water to obtain the final concentration of  100 µg/ml (Stock solution 
B). From the stock solution B 0.5 ml of solution is pipetted in to a 10.0ml 
volumetric flask and then the resultant solution is also analysed as per the 
procedure and was statically validated using the regression equation   
 
Fig. 7: The graph showing the maximum absorbance method 4 
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PART B: SIMULTANEOUS ESTIMATION OF LAMIVUDINE, 
ZIDOVUDINE AND EFAVIRENZ BY UV- SPECTROPHOTOMETRY 
Method 5:  ESTIMATION LAMIVUDINE, ZIDOVUDINE AND 
EFAVIRENZ BY THREE WAVELENGTH SPECTROPHOTOMETRY 
5.1 PRINCIPLE INVOLVED 
The principle involved is the Overlain spectra suggest that lamivudine, 
zidovudine and efavirenz show absorbance maximum at 271.7 nm, 264 and 
246 nm (Fig.8) and efavirenz does not show absorbance at 265 nm (Ȝmax of 
zidovudine) and 271.7 nm (Ȝmax of lamivudine ) lamivudine and zidovudine was 
estimated by simultaneous equations. Efavirenz is estimated at 246 nm. For this 
purpose the standard calibration curve of efavirenz was prepared at 246 nm in 
the concentration range of 2-20 ȝg/ml. A reference solutions containing exactly 
the same concentration of lamivudine and zidovudine as determined from the 
absorbance measurement at 271.7 nm and 264 nm was prepared. The 
absorbance of the sample solution containing lamivudine, zidovudine and 
efavirenz was measured at 246 nm against the reference solutions containing 
lamivudine and zidovudine. 
5.2 EQUATIONS 
                                CX = (A2ay1-A1ay2) ------- equation 1 
                
                           (ax2ay1 - ax1ay2) 
 
                                         CY =  (A2ay1-A1ay2) ------- equation 2 
         
                           (ax2ay1 - ax1ay2) 
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Where      Cx = concentration of lamivudine  
                 Cy = concentration of zidovudine  
                 ax1 and ax2 are the absorptivity of lamivudine at 271.1nm and 264 nm 
                 ay1 and ay2 are the absorptivity of zidovudine at 271.1nm and 264 nm 
                 A1= absorbance of lamivudine at 271.1nm 
                 A2= absorbance of lamivudine at 264 nm 
5.3 REAGENTS USED 
5.3.1 Selection of solvent (95% methanol) 
After assessing the solubility of drug in different solvents 95% methanol was 
used as common solvent for developing spectral characteristics. 
5.4 PREPARATION OF STANDARD CALIBRATION CURVE  
5.4.1 Preparation of standard stock solution 
The standard stock solution of lamivudine, zidovudine and efivarenz was 
prepared by dissolving 25 mg of each drug in 25 ml volumetric flask and 10 ml 
of methanol was added to it and sonicated for 5 minutes and the volume was 
made up to 25 ml with methanol (Stock solution A). 0.1 ml of the stock 
solution A was taken into a 10 ml volumetric flask and further diluted to get 
standard solutions of 10 ȝg/ml. 
5.4.2 Preparation of calibration curve 
Aliquots of LAM, ZVD and EFZ ranging from 0.2-2 ml (2.0- 20 µg/ml) were 
pipette into as series of 10ml volumetric flask. The volume was made up to the 
mark at with methanol the absorbances were measured at 271.7 nm, 264 nm 
and 246 nm respectively for LAM, ZVD and EFZ. The amount of LAM, ZVD 
and EFZ present in the sample solution was computed from its calibration 
curve the calibration curve was constructed by plotting absorbance against the 
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initial concentration of LAM, ZVD and EFZ. The linearity range or Beer’s 
range follows in the range between 2.0- 20 µg/ml. The content of LAM, ZVD 
and EFZ was calculated either from the calibration graph or corresponding 
regression equation. Overlain spectra suggest that lamivudine and efavirenz 
and zidovudine show absorbance maximum at 271.7 nm, 264 and 246 nm and 
efavirenz does not show absorbance at 265 nm (Ȝmax of zidovudine) and 271.7 
nm (Ȝmax of lamivudine ) lamivudine and zidovudine was estimated by 
following simultaneous equations. 
 Efavirenz is estimated at 246 nm. For this purpose the 
standard calibration curve of efavirenz was prepared at 246 nm in the 
concentration range of 2-20 ȝg/ml. A reference solutions containing exactly the 
same concentration of lamivudine and zidovudine as determined from the 
absorbance measurement at 271.7 nm and 264 nm was prepared. The 
absorbance of the sample solution containing lamivudine, zidovudine and 
efavirenz was measured at 246 nm against the reference solutions containing 
lamivudine and zidovudine. The concentration of efavirenz is obtained from 
the calibration curve plotted at 246 nm. 
           5.5 ANALYSIS OF TABLET DOSAGE FORM 
Twenty tablets (LAZID-E) were taken, their average weight was determined, 
and were crushed to fine powder. Then powder equivalent to 50 mg of 
lamivudine and 100 mg of zidovudine was put into a 100 ml volumetric flask 
and dissolved in 30 ml methanol with vigorous shaking for 5-10 minutes. 
Finally volume was adjusted with same solvent up to 100 ml. This solution was 
transferred to a 100 ml of volumetric flask through a whatman #41 filter paper. 
The residue was washed twice with methanol, and combined filtrate was made 
58 
 
up to the 100 ml mark with methanol. The solutions were further diluted with 
methanol to get a solution containing 10 ȝg/ml of lamivudine. This was 
analyzed at 271.7 nm and 264 nm wave lengths and the values of absorptions 
were substituted in equations 1 and 2 to obtain the content of lamivudine and 
zidovudine. Having determined the concentration of lamivudine and 
zidovudine reference solutions containing exactly the same concentrations of 
lamivudine and zidovudine (ȝg/ml) as contained in the stock solution was 
prepared. The absorbance of the stock solution was measured at 246 nm against 
reference solution in the spectrum mode of the instrument and the 
concentration of efavirenz was obtained from the calibration curve of 
efavirenz.  
 
Fig. 8:  Overlain spectra of efavirenz, lamivudine and zidovudine.  
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PART C: RP-HPLC METHOD 
Method 6: SIMULTANEOUS ESTIMATION OF LAMIVUDINE, 
ZIDOVUDINE AND NEVIRAPINE  
6.1 PRINCIPLE INVOLVED 
The principal involved in HPLC is, when a mixture of two components is 
applied on the stationary phase, the components with strong affinity for 
stationary phase binds to it and the one with less affinity for stationary phase 
separated out. The degree of separation depends on the surface area of the 
adsorbent so the particle size of the column should be small. 
6.2 EQUATIONS 
Amount in mg found (F) = TWP
W
D
D
W
spl
spl
std
spl 
100A
A
 
std
spl
 
Theoretical plates (N) = 5.54(t/w) 
Tailing factor (Tf) = W0.05 / 2f 
% area difference = 100
Ai
AiAf
 
6.3 REAGENTS USED 
6.3.1 Phosphate buffer pH 3  
Potassium dihydrogen phosphate was used to prepare phosphate buffer. 340 
mg of potassium dihydrogen ortho phosphate was accurately weighed and 
transferred into a 250 ml volumetric flask to obtain 0.01M solution and finally 
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the PH was adjusted to 3 by adding drop by drop orthophosphoric acid 
(Maximum up to 2 drops). 
6.4 PREPARATION OF STANDARD CALIBRATION CURVE 
6.4.1 Preparation of standard stock solution 
Standard stock solution (1000 ȝg/ml) of Lamivudine, Zidovudine and 
Nevirapine were prepared separately in methanol. The working standard 
solutions were prepared and further diluted so as to contain a mixture of 
Lamivudine, Zidovudine and Nevirapine, within the linearity range from 5.0-
100.47 ȝg/ml for lamivudine, 10.0-170.0 ȝg/ml for zidovudine and 5.0-60.0 
ȝg/ml for nevirapine respectively. 
6.4.2 Preparation of calibration curve 
Aliquots of LAM, ZVD and NVP ranging from 0.1- 2 ml (2.0- 100 µg/ml) 
were pipette into as series of 10ml volumetric flask. The volume was made up 
to the mark at with methanol the absorbances were measured at 280.0 nm. The 
amount of LAM, ZVD and NVP present in the sample solution was computed 
from its calibration curve the calibration curve was constructed by plotting 
absorbance against the initial concentration of LAM, ZVD and NVP. Linearity 
was 5.0-100.47 ȝg/ml for lamivudine, 10.0-170.0 ȝg/ml for zidovudine and 
5.0-60.0 ȝg/ml for nevirapine respectively. 
6.4.3 Chromatographic conditions maintained  
The quantification was carried out using Shimadzu HPLC 2010, C18 (250 × 
4.6mm, 5ȝ) column and mobile phase comprising of methanol and phosphate 
buffer (pH 3) in proportion of 45:55 (v/v). Flow rate was maintained at rate of 
0.8 ml/min and the effluent was monitored at 280 nm. The retention time of 
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Lamivudine Zidovudine and Nevirapine were 3.12, 5.01 and 7.08 min 
respectively. The software used was LC solution. 
6.5 ANALYSIS OF TABLET DOSAGE FORM 
Ten tablets, CYTOM-N (ALKEM), each containing 150 mg of Lamivudine, 
300 mg of Zidovudine and 200 mg of Nevirapine were weighed and finely 
powdered. Powder equivalent to 15 mg of Lamivudine, 30 mg of Zidovudine 
and 20 mg of Nevirapine was weighed respectively and transferred to a 
standard volumetric flask. The contents were mixed thoroughly and filtered 
through a 0.45 ȝm membrane filter. 10 ȝl of the sample was injected in to 
HPLC system for the analysis. The results are reported in Table 15. The 
chromatogram of tablet is as shown in figure 10.    
 
 
 
 
Fig. 9: Typical Chromatogram of Lamivudine, Zidovudine and 
Nevirapine in mixed standard solution 
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Fig. 10: Typical Chromatogram of Lamivudine, Zidovudine and 
Nevirapine in Tablet dosage form 
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            PART D: GC METHOD  
Method 7: ESTIMATION OF LAMIVUDINE BY GAS 
CHROMATOGRAPHIC METHOD USING ETHYL 
CHLOROFORMATE AS A DERIVATIZING REAGENT  
7.1 PRINCIPLE INVOLVED 
LMV analysis was performed after derivatization with ECF (precolumn 
derivatization). The method development for the assay of LMV was based on 
its chemical properties. LMV is a polar molecule and, therefore, a polar 
solvent methanol was used as the diluent. PHZ was used as an internal 
standard. The capillary column coated with 5% diphenyl/ 95% dimethyl 
polysiloxane is a good choice for separation of this analyte since they elute as 
symmetrical peaks at a wide range of concentrations. 
The compounds LMV and PHZ reacted with reacted with ECF to form a 
volatile product (scheme 5) and eluted from a capillary GC column, each has 
single peak. The reaction was carried out in methanol. A better GC response 
(average peak height/peak area) was observed using an aqueous solution 
containing pyridine as the reaction medium. The effect of pH on the 
derivatization was examined between 1-10 at unit interval.  
 
 
 
 
64 
 
7.2 REACTION INVOLVED  
                   (a) 
Cl O
O
 
                   (b) 
Cl O HN NH NH
N
NO
O
S
HO
O
 
                   (c) 
Cl O NH
O
NH NH
O
N
 
 
Scheme  5: Structure diagram of the derivative of ECF (a) ECF (b) LMV (c) 
PHZ 
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  7.3 REAGENTS USED 
7.3.1 Phenyl Hydrazone (Internal standard):  
1mg of phenyl hydrazone was accurately weighed and transferred into a 10 ml 
volumetric flask and further 0.5 ml was withdrawn and transferred into 
another 10ml volumetric flask to get a final concentration of 0.05 mg/ml.  
7.3.2 Chloroform: Normal chloroform of analytical quality from Mark was 
used for extraction.  
7.3.3 Ethyl Chloroformate 
Ethyl chloroformate (ECF) was used as a precolumn derivitizing reagent. 
7.4 PREPARATION OF STANDARD CALIBRATION CURVE 
7.4.1 Preparation of standard stock solution 
Accurately weighed 100.0 mg of LMV (bulk drug) was dissolved in 10.0 ml 
of methanol in 100 ml volumetric flask and sonicated for about 15min to 
enhance the solubility and volume was made up to the mark with methanol i.e. 
1.0 mg/ml (Stock solution A). 
7.4.2 Preparation of calibration curve 
From the stock solution A serial dilutions were done to obtain 10 to 50 ng/ml. 
Internal standard phenyl hydrazone 0.05 mg/ml was prepared. The different 
concentrations of the internal standards resulted from adjustment of the height 
of its peaks to those of analytes. The solutions were kept at low temperatures 
and were protected from light. To each volumetric flask ethyl chloroformate 
1ml was added and further heated to 70˚C for 5 minutes. The solutions were 
further extracted for with chloroform and redissolved in methanol 
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7.4.3 Chromatographic conditions  
GC studies were carried out on SHIMADZU model 2014 (shimadzu 
Technologies, Japan) coupled with a split/split less injector, operated in a 
split-mode and FID. The computer with GC solutions software controlled the 
gas chromatograph, and a Cannon laser printer was used. Rtx-5 capillary 
column (cross bond 5% diphenyl/ 95% dimethyl polysiloxane) with a length 
of 30 meters and an internal diameter of 0.25 mm was used throughout the 
study. 
The GC-FID parameters used in the method development were based on the 
boiling point. The injection port and detector temperature were set to 100˚C 
and 250˚C, respectively. Different temperature programs were investigated for 
GC oven. The end of this investigation, the best temperature program was 
selected for a good resolution. 
Manual split injection (split ratio 4:1) of approximately 3 ȝl sample was 
performed at an inlet temperature of 150˚C. The detector temperature was set 
to 250˚C. After injection the oven temperature was increased quickly from 
50˚C to 100˚C, which was held for 1 min, then programmed within 5 min to 
250˚C at a rate of 20˚C per min which was held for 4min. 
Nitrogen at a flow rate of 2 ml/min was used as a carrier gas. Synthetic air 
(flow rate of 100 ml/min), hydrogen (25 ml/min) were fed to the FID. All the 
gases used in these studies were of Pharamcopoeial purity.  
7.5 ANALYSIS OF TABLET DOSAGE FORM 
The studies were conducted on the drug LMV, Hepitec (100mg, GSK) and 
Viramid (100mg, Lupin). The tablets were powdered, and an amount of 
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powder equivalent to the average weight of a tablet was mixed with methanol 
and shaken for 15 min at a frequency of approximately 3 cycle’s s-1. The 
solution was then filtered through 0.2 ȝm whatman filter paper. The prepared 
solutions were of concentration 10 , 30 and 50 ng/ml, sample solution were 
obtained by following the same procedure as in the construction of calibration 
graph. The solutions were heated to 70˚C for 5 minutes. Further the solutions 
were extracted with chloroform and redissolved in methanol. The internal 
standard of concentration 50 ȝg was added to each of the sample solution. The 
chromatogram obtained is shown in the fig.12.  
 
            Fig. 11: Chromatogram obtained from Lamivudine (LMV) and Phenyl  
hydrazine (PHZ) solution, Methanol (A), ethyl chloroformate (B), 
lamivudine (C) and phenyl hydrazine (D). 
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Fig.12: Chromatogram obtained from Lamivudine (LMV) tablet solution. 
Methanol (A), ethyl chloroformate (B), lamivudine tablet (C) and phenyl 
hydrazine (D). 
 
 
 
5. RESULTS 
PART A: UV-VISIBLE SPECTROPHOTOMETRIC METHODS FOR 
LMV AND STV 
Method 1: Estimation of lamivudine by MBTH reagent 
Method 2: Estimation of lamivudine by Bromophenol blue dye  
Table 1: Analytical and validation parameters for the assay of LMV 
 
Parameter Method 1 Method 2 
Colour Red Green 
Ȝmax(nm) 595 nm 659 nm 
Beer’s law range (ȝg/ml) 1-5 1-7 
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Molar absorptivity(L mol-1 cm-1) 0.6075x103 0.286 x 103 
Limit of detection  (ȝg/ml) 0.1 0.3 
Limit of quantification (ȝg/ml) 0.3 0.9 
Intercept 0.050 0.045 
Slope b ± Sb 0.0023 0.0013 
Correlation coefficient, R 0.9913 0.9967 
 
   Table 2: Intra-day precision and intra-day error of the methods 1 and 2 
 
Method LMV(ȝg/ml) 
taken 
LMV(ȝg/ml) 
found 
Relative error 
(%) 
RSD (%) 
 
1 0.9 0.6 0.4 
BPB 2 1.92 0.13 0.2 
 
3 2.89 0.1 0.2 
 
4 3.91 0.15 0.1 
MBTH 5 4.96 0.11 0.1 
 
6 5.88 0.25 0.1 
 
7 7.97 0.25 0.1 
 
Table 3: Assay of drug in pharmaceutical formulations (tablets) 
 
Preparation Label claim  (mg 
per tablet) 
 
Percentage found (%)+ SD 
 
 
 MBTH (Method 1) BPB (Method 2) 
VIROLAM 100 99.9±0.5 99.8±0.5 
LAMIDAC 100 99.9±0.4 99.6±0.4 
LAMIVIR 150 99.9±0.2 99.4±0.2 
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Method 3: Estimation of stavudine by selective oxidation using Cerium (IV) 
ammonium sulphate 
Method 4: Estimation of stavudine by 2, 6-Dichloroquinone Chlorimide 
(Gibbs regent)  
Table 4: Optical characteristics of spectrophotometric methods 3 and 4 
 
 
 
 
 
 
Parameter Method 3 Method 4 
Color Colourless  Yellow colour 
Ȝmax(nm) 282 528 
Beer’s law range (ȝg/ml) 2-10 2-12 
Molar absorptivity (l mol-1cm-1) 3.17 x 104  3.32 x 104 
Sandell’s sensitivity  (µg cm-2) 0.170212 0.0775 
Limit of detection  (ȝg/ml) 0.8712 0.984 
Limit of quantification (ȝg/ml) 2.64 2.98 
Correlation coefficient, R 0.991 0.9967 
Slope b 0.010 0.055 
Intercept a 0.184 0.158 
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Table 5: Results of determination of STV in formulations and statistical 
comparison for method 3 and method 4 
 
Pharmaceutical 
 dosage form 
Labelled 
Amount 
Amount found by 
proposed methods (mg) 
 
Stadine (Emcure, 
ARV), 
Method-3 
Method-4 
 
 
 
100 mg 
100 mg 
 
 
99.6 
99.8 
Stag (Hetero, Genx) 
Method-3 
Method-4 
 
 
  100 mg 
  100 mg 
 
                   98.1 
99.7 
Virostav (Ranbaxy, 
India) 
Method-3 
Method-4 
 
 
 
100 mg 
100 mg 
 
 
98.91 
99.4 
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Table 6: Accuracy and method precision data for the developed method 3 and 4 
SD: Standard deviation; SEM. Standard error of mean; RSD. Relative standard  
Deviation; a. intraday precision, b. inter day precision. 
 
 
 
 
 
 
 
 
 
 
 
 
Drug S.no Label 
Clai
m 
(mg) 
Amount 
found* 
% 
Purity* 
Avera
-ge 
(%) 
S.D R.S.Da RSDb S.E.M 
Method-3 
 
Stadine 
(stavudine) 
1  
 
 
100 
98.642  99.321 99.47 0.4344 
 
0.4379 
 
0.8456 0.1773 
2 101.604  100.82 
3 97.057  100.05 
4 98.542  99.271 
5 94.164  97.082 
6 100.604  100.30 
Method –4 
 
Stag 
(stavudine) 
1  
 
100 
97.17 99.8 98.34 0.376 0.362 0.723 0.124 
2 100.2 100.43 
3 94.23 96.22 
4 98.22 99,16 
5 99.21 99.43 
6 99.53 99.23 
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Table 7: Comparison of the results between  methods proposed 3 and 4 
Parameter Method-3 Method-4 
Percentage recovery (%) 99.20 99.41 
Accuracy 99.47 98.34 
Standard deviation 0.4344 0.376 
Standard error of mean 0.1773 0.124 
intraday precision 0.4379 0.362 
inter day precision 0.8456 0.723 
 
PART B: SIMULTANEOUS ESTIMATION OF LAMIVUDINE, 
ZIDOVUDINE AND EFAVIRENZ BY UV- SPECTROPHOTOMETRY 
Method 5: By Three wavelength spectrophotometry 
Table 8: Optical characteristics data and validation parameters of method 
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Parameters Values 
Lamivudine Zidovudine Efavirenz 
Working Ȝmax 271.7 nm 265 nm 246nm 
Beers law limit (ȝg/ml) 2-20 2-20 2-20 
Absorptivity* 0.0726 0.0298 0.0179 
Correlation coefficient* 0.979 0.990 0.974 
Intercept* 0.0312 0.0673 -0.038 
Slope* 0.351 0.117 0.108 
LOD*(ȝg/ml) 0.106 0.051 0.148 
LOQ*(ȝg/ml) 0.324 0.28 0.432 
Intra-day* (precision) 
(%COV) 
0.275 0.231 0.341 
Inter-day (precision) 
(%COV) 
0.983 0.986 0.670 
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Table 9: Result of recovery studies of method 5 
Method Recovery 
level 
(Added 
amount) 
Percent recovery ± SD # 
 Lamivudine Zidovudine Efavirenz  
Three wavelength 
spectrophotometry 
80% 98.99 ± 
0.0456 
100.20 ± 
0.1045 
101.20 ± 
0.355 
100% 99.85 ± 
0.0345 
101.20 ± 
0.7567 
98.97 ± 
0.432 
120% 99.50 ± 
0.2321 
100.10 ± 
0.6578 
98.90 ± 
0.870 
# Average of three estimations at each level of recovery, SD: standard 
deviation  
Table 10: Analysis data of tablet Formulation of method 5 
Method  Drug Label 
Claim 
mg/tab 
Amount 
found* 
mg/tab 
Label 
claim 
(%) 
S.D* % 
COV 
Three wavelength 
spectrophotometry 
LMV 150 148.23 99.03 0.6574 0.634 
ZDV 300 299.99 99.95 0.4522 0.462 
EFZ 600 600.23 100.38 0.162 0.151 
* Average of six estimations of tablet formulation, COV coefficient of 
variation 
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PART C: RP-HPLC METHOD 
Method 6: Simultaneous estimation of lamivudine, Zidovudine and 
Nevirapine  
Table 11: Determination of Lamivudine, Zidovudine and Nevirapine in 
Tablet dosage form of method 6 
 Label 
Amount(mg) 
Amount(ȝg) 
Taken 
Found %RSD %W/W 
Lamivudine 150 15 149.67  0.211 99.7 
Zidovudine 300 30 298.82  0.118 99.6 
Nevirapine 200 20 19.86 0.266 99.3 
 
Table 12: Recovery Studies of Lamivudine, Zidovudine and Nevirapine of 
method 6 
Name of the 
Drug 
Sample 
ID 
Amount 
added 
(ȝg/ml) 
Amount 
recovered 
(ȝg/ml) n=3 
Percentage 
recovery 
Average 
percentage 
recovery 
 
Lamivudine  
80% 10 9.84 98.4  
98.67 100% 15 14.8 98.6 
120% 20 19.8 99.0 
 
Zidovudine 
80% 20 19.7 98.5  
98.23 100% 30 28.9 96.5 
120% 40 39.89 99.72 
 
Nevirapine 
80% 10 9.98 99.8  
98.53 100% 20 19.3 96.5 
120% 30 29.8 99.3 
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Table 13: Intraday Precision of Lamivudine, Zidovudine and Nevirapine 
of method 6 
Parameters Lamivudine Zidovudine Nevirapine 
Mean 236.335 2.567 1.0 
S.D 0.6819 0.0228 0.0089 
%RSD 0.288 0.88 0.89 
 
Table 14: Inter day Precision of Lamivudine, Zidovudine and Nevirapine 
of method 6 
Parameters Lamivudine Zidovudine Nevirapine 
Mean 236.99 2.642 1.015 
S.D 0.058137 0.02682 0.00268 
%RSD 0.02453 1.015 0.264 
 
         Table 15: LOD and LOQ of Lamivudine, Zidovudine and Nevirapine of 
method 6 
Parameters Lamivudine 
(ȝg) 
Zidovudine 
(ȝg) 
Nevirapine (ȝg) 
Limit of detection 0.116 0.129 0.018 
Limit of quantitation 0.348 0.388 0.055 
 
Table 16: System Suitability Parameters of method 6 
Parameters Lamivudine Zidovudine Nevirapine 
Theoretical 
plates/meter 
793.641 1218.767 1353.339 
HETP 189.002        123.007 110.873 
Tailing factor 1.638         1.801 2.105 
Rt                          3.12          5.01                        7.08 
Resolution 0.0 3.670 2.985 
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           PART D: GC METHOD  
Method 7: Estimation of Lamivudine by Gas Chromatographic method using 
Ethyl Chloroformate as a Derivatizing reagent  
Table 17: Retention times of LMV and PHZ of method 7 
Compound name Retention time (min) 
Lamivudine 4.5 
Phenyl hydrazine 6.8 
 
Table 18: Results from analysis of LMV in pure drug of method 7 
Parameter Value 
Linearity (ng) 10-50 
LOD (ng) 0.54 
LOQ (ng) 1.64 
Precision 1.53 
Recovery % 99.2 
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Table 19: Precision and accuracy of LMV by GC-FID method 
Added 
amount 
(ng/ml) 
Within-day Between-day 
Found 
±SD 
(ng/ml) 
Accuracy Precision 
RSD%a 
Found ±SD 
(ng/ml) 
Accuracy Precision 
RSD% a 
10 10.12 ± 
0.039 
3.20 3.02 9.87±0.05 4.80 3.82 
20 20.42± 
0.136 
1.47 1.79 20.12±0.172 2.93 2.23 
30 31.21± 
0.391 
4.56 1.52 30.31±0.752 5.12 2.86 
 
SD: Standard deviation of six replicate determinations, RSD: Relative 
standard deviation, 
a average of six replicate determinations, Accuracy: (%relative error) (found-
added)/added x100 
 
Table 20: Recovery values of LMV by GC-FID method in pharmaceutical 
preparations 
Commercial preparation LMV tablet 
Method Added (ng/ml) Found ±SD 
(ng/ml) 
Recovery (%) RSD% a 
GC-FID 10 9.52 ± 0.192 96.5.0 3.78 
15 15.13 ± 0.263 100.86 2.59 
20 20.11 ± 0.631 101.2 2.47 
SD: Standard deviation of six replicate determinations, RSD: Relative 
standard derivation 
a average of six replicate determinations 
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6. DISCUSSION 
Method 1: Estimation of lamivudine by MBTH reagent 
Method 1 is based on the oxidation followed by coupling of 3-methyl-
2-benzothiazolinone hydrazone with LMV in the presence of ferric chloride to 
form a green colored chromogen. Actually, this is an iron catalyzed oxidative 
coupling reaction of MBTH with the drug. Under reaction conditions, on 
oxidation, MBTH loses two electrons and one proton forming an electrophilic 
intermediate, which is the active coupling agent. This intermediate undergoes 
electrophilic substitution with the drug to form the colored product. The 
reaction path way is represented in scheme 1. The linearity range or Beer’s 
range follows in the range between 1 to 8 µg/ml (Fig.1) 
Effect of MBTH Concentration 
The studying of MBTH concentrations revealed that the reaction was 
dependent on MBTH reagent (Fig.2). The absorbance of the reaction solution 
increased as the MBTH concentration increased, and the highest absorption 
intensity was attained at MBTH concentration of 0.5 % (w/v). Higher MBTH 
concentrations up to 1.25 % had no effect on the absorption values. Further 
experiments were carried out using 0.5 % MBTH.  
Effect of FeCl3 Concentration 
The studying of FeCl3 concentrations revealed that the reaction was dependent 
on FeCl3 reagent (Fig.2). The absorbance of the reaction solution increased as 
the FeCl3 concentration increased, and the highest absorption intensity was 
attained at FeCl3 concentration of 1 % (w/v). Higher FeCl3 concentrations up 
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to 1.6 % had no effect on the absorption values. Further experiments were 
carried out using 1 % FeCl3.  
Method 2: Estimation of lamivudine by Bromophenol blue dye (BPB). 
The method is based on the application of acidic dyes for the 
spectrophotometric determination of LMV. The structural formula of LMV 
feature amine group, suggests the use of acidic dyes (BPB) as chromogenic 
reagents. The acid dye technique is a general procedure for the quantitative 
analysis of a variety of pharmaceutical amines. In practice, an aqueous 
solution containing the amine and a suitable indicator dye is shaken with an 
organic solvent. The concentration of the resulting ion-pair is then determined 
spectrophotometrically. Few studies have reported the analysis of 
pharmaceutical compounds through formation of ion-pair, without extraction, 
followed by spectrophotometric estimation. The reaction path way is 
represented in scheme 2. When added in increasing concentrations of LMV to 
a fixed concentration of BPB there is a proportional increase in absorbance at 
the respective Ȝmax. Preliminary experiments were performed to fix the upper 
concentrations of the dye that could be determined spectrophotometrically. 
 
Effect of BPB Concentration 
Various concentrations of BPB were tried and the absorbance maximum was 
found with 0.1% of BPB. Higher BPB concentrations up to 1 % had no effect 
on the absorption values. Further experiments were carried out using 0.1 % 
BPB
. 
The colour intensity increased with time. The maximum absorbance was 
seen only after 5 minutes and there was stable after 5 minutes as shown in the 
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(Fig. 5.) All the experimental procedures were carried out in room 
temperature. 
 
 
Method 3: Estimation of stavudine by selective oxidation using Cerium 
(IV) ammonium sulphate 
Cerium (IV) and iron (III) ammonium sulphates are strong oxidizing agents 
and are utilized extensively for the determination of organic compounds. The 
reagent blank has negligible absorbance in the range used for detection of the 
STV. Beer’s law is obeyed in the range of 2–10 ȝg/ml. The apparent molar 
absorptivity of the drug was found to be 3.17 x 104 l mol-1cm-1. STV on 
oxidation with Cerium (IV) or iron (III) in acidic medium had shown a 
maximum absorption at 282 nm with the reagents (Scheme 3). 
 
Method 4: Estimation of stavudine by 2, 6-Dichloroquinone Chlorimide 
(Gibbs regent)  
Oxidation of STV was attempted in the present study for the development of 
spectrophotometric method for its determination. The method 4 is based on the 
reaction between the Gibb’s reagent and STV. The Gibb’s reagent reacts with 
STV and results in the formation of yellow colored complex (Scheme 4). The 
reagent blank has negligible absorbance in the range used for detection of the 
STV. Beer’s law is obeyed in the range of 2–12 ȝg/ml. The apparent molar 
absorptivity of the drug was found to be 3.32 x 104 l mol-1cm-1. Optimization 
of the spectrophotometric conditions was intended to take into account the 
various goals of method development. Analytical conditions were optimized 
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via a number of preliminary experiments. The effect of the Gibb’s reagent 
concentration was studied and found that 0.5% gave good absorbance values 
so further experiments were carried out using 0.5 %  Gibb’s reagent. 
Method 5: By Three wavelength spectrophotometry 
During the time of preparation of samples the maintenance of room 
temperature and the samples should be freshly prepared. The samples prepared 
before 3 days cannot be used as the drug had shown a reduce in absorbance at 
its maximum absorption point. The standard solution are prepare only between 
2-20 ȝg/ml above this range the absorbances were out of Beer’s range.  
The validity and reliability of proposed methods are assessed by recovery 
studies. Sample recoveries for both the methods are in good agreement with 
their respective label claims, which suggest non-interference of formulation 
additives in estimation. 
 
Method 6: Simultaneous estimation of lamivudine, Zidovudine and 
Nevirapine by HPLC  
Present study indicates the suitability of reversed-phase column procedure for 
the simultaneous determination of Lamivudine, Zidovudine and Nevirapine in 
combined dosage form. The chromatographic conditions were optimized by 
making a change in mobile phase composition, change in pH, and changes in 
the buffers used in the mobile phase. Different ratios phosphate buffer and 
methanol were experimented in order to optimize the mobile phase. Finally a 
mixture of methanol and phosphate buffer (adjusted to pH-3) in the ratio of 
55:45 was taken into consideration. All system suitability parameters 
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(Theoretical plates, tailing factor and resolution) were accurate. The run time 
was set at 10 min as the three drugs appeared on the chromatogram below 10 
min. The developed LC method was found to be specific for simultaneous 
estimation of Lamivudine, Zidovudine and Nevirapine. 
Method 7: Estimation of Lamivudine by Gas Chromatographic method 
using Ethyl Chloroformate as a Derivatizing reagent  
LMV analysis was performed after derivatization and the internal standard 
technique was used for computation. The method development for the assay of 
LMV was based on its chemical properties. LMV is a polar molecule and, 
therefore, a polar solvent methanol was used as the diluent. The capillary 
column coated with 5% diphenyl/ 95% dimethyl polysiloxane is a good choice 
for separation of this analyte since they elute as symmetrical peaks at a wide 
range of concentrations.  
 The compounds LMV and PHZ reacted with reacted with ECF to form 
a volatile product (Scheme 5) and eluted from a capillary GC column, each 
has single peak. The reaction was carried out in methanol. A better GC 
response (average peak height/peak area) was observed using an aqueous 
solution containing pyridine as the reaction medium. The effect of pH on the 
derivatization was examined between 1-10 at unit interval. It was observed 
that derivatization occurred at pH value above 6. The reaction mixture was 
sonicated at room temperature (30˚C) for 5-20 min at an interval of 5 min and 
the optimum response was observed within 15 min. Chloroform was used for 
extraction of derivatives, as reported for related compounds. The recovery 
studies were done and the percentage recovery of LMV was found to be 
99.2% 
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7. SUMMARY 
Several drugs are available in the form of pharmaceutical formulations to 
control diseases. Methods of assay for controlling the concentration of these 
chemicals in the medicine and in the living body are necessary. Pharmaceutical 
analysis occupies a pivotal role in statutory certification of drugs and their 
formulations either by the industry or by the regulatory authorities. The complexity of 
the problem encountered in pharmaceutical analysis coupled with importance of 
achieving the selectivity, speed, cost, simplicity, precision and accuracy results in new 
methods of analysis being quickly adopted by pharmaceutical industry. 
Formulations containing combinations of drugs for potentiating or 
complementing another in therapy are on the increase. In some cases, no precise 
analytical methods are reported and quite often the reported procedures need 
improvements or changes keeping in the view of the advances. 
Among several instrumental techniques (HPLC, GC, Fluorimetry, NMR, mass 
spectroscopy covering IR, UV and visible regions) available for assay of drugs, 
visible spectrophotometric methods depend only on the nature of chemical reaction 
utilized for colour development and not on sophistication of the equipment. GC 
method is highly selective and sensitive compared to spectroscopic or other 
chromatographic methods. GC method is also cost effective as expensive solvents are 
not required and it is a versatile tool for qualitative and quantitative analysis of drugs 
and pharmaceuticals. 
Due to the importance of analysis, present analytical method has been 
developed for some of the widely used antiretroviral drugs such as lamivudine, 
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zidovudine, stavudine, nevirapine and efavirenz. Hence we planned o develop HPLC, 
GC and spectrophotometric methods. 
There is a wide scope for the development of new analytical methods for the 
assay of the antiretroviral drugs. Spectrometric (part A&B), HPLC (part C) and GC 
(part D) techniques have been used as a tool in the present thesis work. The above 
tools have been used for the development of new analytical methods for the assay of 
drugs mentioned by exploiting their characteristics, physical and chemical properties 
(dependent on basic moieties and functional groups present in each drug). 
The contents of the thesis have been divided into eight chapters and 
appropriate reference has been placed at the end of the ninth chapter.  
Chapter-1 opens with the introduction giving a brief account of various 
aspects like chemotherapy, instrumental methods, concepts of spectroscopy, various 
reagents, types of chromatographic methods and method validation. The introduction 
includes brief account on selected drugs. 
Chapter- 2 explains the objective of present investigation adopted for selected 
drug. 
Chapter-3 for review of literature gives details on reported methods, clinical 
studies under different experimental conditions, drug introduction and therapeutic 
importance of selected drug for present work. Also it gives information about the 
necessity to investigate new analytical methods for Lamivudine, Zidovudine, 
Stavudine, Nevirapine and Efavirenz for the quantitative estimation. 
Chapter-4 contains four parts.  Part A gives information regarding UV 
spectroscopic method (1 - 4). It briefly explains about principle involved in the 
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method, proposed reaction, reagents and materials used, preparation of standard 
solutions, preparation of calibration curve, analysis of tablet dosage form. Primary 
amine group in Lamivudine was exploited in the present investigations for the 
development of the methods. 
In method 1 method is based on oxidation followed by coupling of 3-methyl-
2-benzothiazolinone hydrazone (MBTH) with LMV in the presence of ferric chloride 
to form green colored chromogen exhibiting absorption maximum at 659 nm.  
In method 2 method is based on the interaction of LMV with 0.1% methanolic 
solution of bromophenol blue (BPB) to form a stable, red-colored, ion-pair complex 
peaking at 595 nm  
In method 3 method is based on the selective oxidation of this drug with either 
CeIV in acid medium and shown absorption maxima at 282 nm.  
In method 4  method is based on the formation of a colored oxidative coupling 
product between 2, 6-dichloroquinone chlorimide and the drug; it had shown absorption 
maxima at 528 nm. The method obeyed Beer’s range in a concentration range of 2-12 ȝg/ml.  
Part B describes the simultaneous estimation of lamivudine, zidovudine and 
efavirenz in pure and tablet dosage form by using methanol as a solvent was 
developed and validated. LMV, ZVD and EFZ shown absorbance maximum at 271.7 
nm, 264 nm and 246 nm. Validation study reveals that the method is specific, 
accurate, precise and reproducible. All the three drugs obey Beer’s law in the 
concentration range 2 ȝg to 20 ȝg. 
Part C describes the HPLC method for assay of LMV, ZVD and NVP in bulk 
and tablet formulation is carried out. The assay method is found to be specific for the 
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LMV, ZVD and NVP tablets. The method is found to be linear in the specified range 
for LMV, ZVD and NVP tablets. 
 Part D describes the a novel gas chromatographic (GC) method has been 
developed for the quantitative estimation of lamivudine (LMV) both in bulk drug and 
pharmaceutical dosage forms. Ethyl chloroformate (ECF) was used as a precolumn 
derivitizing reagent. Phenylhydrazine (PHZ) was used as an internal standard. GC 
separation was carried out on a Rtx-5 capillary column (cross bond 5% diphenyl/ 95% 
dimethyl polysiloxane) with a length of 30 meters and a internal diameter of 0.25 mm 
with flame ionization detector. The recovery studies were done and the percentage 
recovery of LMV was found to be 99.2% 
 Chapter 5 explains the results that are divided into four parts.. In part A, B, C 
and D result obtained in each of the UV-Visible spectrophotometric method, HPLC 
and GC method for estimation of Lamivudine, Stavudine, Zidovudine, Nevirapine and 
Efavirenz are summarized in Tables 1-20.  
Chapter 6 consists of discussion which is divided into four parts. Part A and 
B discusses about developed visible spectrophotometric methods. Part C discusses 
about developed HPLC method. Part D discusses about developed GC method. 
Chapter 7 explains the conclusion of the proposed methods for the 
quantitative estimation of Lamivudine, Stavudine, Zidovudine, Nevirapine and 
Efavirenz. A set of seven methods has been developed for the purpose and these 
methods are validated in terms of sensitivity, accuracy and precision. 
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The methods can also be used for the routine determination of Lamivudine, 
Stavudine, Zidovudine, Nevirapine and Efavirenz in bulk drug and pharmaceutical 
formulations. 
Chapter 9 contains the references from which the information of Lamivudine, 
Stavudine, Zidovudine, Nevirapine and Efavirenz and introduction of general 
methodology was collected. 
Chapter 10 contains the list of paper communicated so far to various journals. 
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8. CONCLUSION 
Antiretroviral drugs are medications for the treatment of infection by retroviruses, 
primarily HIV. When several such drugs, typically three or four, are taken in 
combination, the approach is known as highly active antiretroviral therapy, 
or HAART. The American National Institutes of Health and other organizations 
recommend offering antiretroviral treatment to all patients with AIDS.  
Although various UV-visible methods have been reported for the estimation of 
LMV, ZDV and STV it was found that the reagents used in the present study were not 
used and the methods developed are much sensitive and less time consuming 
compared to the methods previously develop. The simultaneous estimation of LMV, 
ZDV and EFZ with UV spectrophotometer using triple point method was not 
investigated. 
The work deals with four UV-Visible spectrophotometric methods i.e. 
oxidation reaction with Cerium (IV) ammonium sulphate, visible spectrophotometric 
method with BPB, GIBBS reagent and coupling reaction with MBTH reagent. 
The methods are validated in terms of sensitivity, accuracy and precision. 
A. Comparative Sensitivity 
         1> 2 > 3 > 4 
B. Comparative accuracy: 
        3> 4 >2 > 1   
C. Comparative precision: 
    3 > 4 > 1 > 2 
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Simultaneous estimation of LMV, ZVD and NVP by RP-HPLC was also 
developed. The retention times of the drugs were less when compared to other 
methods developed.  In terms of sensitivity, accuracy and precision the present 
developed method has shown good results when compared to the existing method. 
Lamivudine was quantified by Gas Chromatographic method using Ethyl 
Chloroformate as a Derivatizing reagent. There were no GC methods reported for 
lamivudine. LMV analysis was performed after derivatization and the internal 
standard technique was used for computation. The method development for the assay 
of LMV was based on its chemical properties. The method developed is very sensitive 
as the limit of detection is very less (Table 18). 
Results of analysis of the pharmaceutical formulations revealed that the 
proposed methods are suitable for their analysis with no interference from the usual 
additives. 
All the methods were found to be linear, precise, accurate, specific and all 
proved to be sensitive, convenient and effective for the determination of LMV, ZVD, 
STV, NVP and EFZ in bulk and pharmaceutical dosage forms. 
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